-
Recent Posts
- Sumitomo Dainippon Pharma Completes the Formation of the Strategic Alliance with Roivant Sciences
- Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance
- Enzyvant Appoints Jeb Ledell as Chief Operating Officer
- Enzyvant Announces FDA Acceptance of Biologics License Application (BLA) and Priority Review Status for RVT-802, a Novel Investigational Tissue-Based Regenerative Therapy for Pediatric Congenital Athymia
- Enzyvant’s Investigational Regenerative Treatment (RVT-802) for Congenital Athymia to be Discussed in Symposium, Platform Presentation and Poster Session at Clinical Immunology Society Meeting
Recent Comments
Archives
Categories
Meta
Category Archives: Archive
No posts found!
Sumitomo Dainippon Pharma Completes the Formation of the Strategic Alliance with Roivant Sciences
Enzyvant Newsrooom | December 2019
Reading Time: 3 minutes
Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance
Enzyvant Newsrooom | November 2019
Reading Time: 5 minutes
Enzyvant Appoints Jeb Ledell as Chief Operating Officer
Enzyvant Newsrooom | October 2019
Reading Time: 2 minutes
Enzyvant Newsrooom | June 2019
Reading Time: 5 minutes
Enzyvant Newsrooom | April 2019
Reading Time: 3 minutes
Enzyvant Appoints Industry Veteran Rachelle Jacques as Chief Executive Officer
Enzyvant Newsrooom | February 2019
Reading Time: 2 minutes
Enzyvant Newsrooom | July 2018
Reading Time: 3 minutes
Enzyvant Receives FDA Rare Pediatric Disease Designation for Investigational Therapy RVT-802
Enzyvant Newsrooom | September 2017
Reading Time: 3 minutes
Enzyvant Newsrooom | April 2017
Reading Time: 3 minutes
Enzyvant to Develop Novel Biologic Therapy for Complete DiGeorge Syndrome
Enzyvant Newsrooom | January 2017
Reading Time: 2 minutes
Enzyvant Newsrooom | July 2016
Reading Time: 4 minutes